Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization

Giulia Girolimetti,Flora Guerra,Luisa Iommarini,Ivana Kurelac,Daniele Vergara,Michele Maffia,Michele Vidone,Laura Benedetta Amato,Giulia Leone,Sabrina Dusi,Valeria Tiranti,Anna Myriam Perrone,Cecilia Bucci,Anna Maria Porcelli,Giuseppe Gasparre

DOI: https://doi.org/10.1093/hmg/ddx186

IF: 5.1214

2017-05-09

Human Molecular Genetics

Abstract:Development of chemoresistance is a cogent clinical issue in oncology, whereby combination of anticancer drugs is usually preferred also to enhance efficacy. Paclitaxel (PTX), combined with carboplatin, represents the standard first-line chemotherapy for different types of cancers. We here depict a double-edge role of mitochondrial DNA (mtDNA) mutations induced in cancer cells after treatment with platinum. MtDNA mutations were positively selected by PTX, and they determined a decrease in the mitochondrial respiratory function, as well as in proliferative and tumorigenic potential, in terms of migratory and invasive capacity. Moreover, cells bearing mtDNA mutations lacked filamentous tubulin, the main target of PTX, and failed to reorient the Golgi body upon appropriate stimuli. We also show that the bioenergetic and cytoskeletal phenotype were transferred along with mtDNA mutations in transmitochondrial hybrids, and that this also conferred PTX resistance to recipient cells. Overall, our data show that platinum-induced deleterious mtDNA mutations confer resistance to PTX, and confirm what we previously reported in an ovarian cancer patient treated with carboplatin and PTX who developed a quiescent yet resistant tumor mass harboring mtDNA mutations.

genetics & heredity,biochemistry & molecular biology